Myocardial Infarction News and Research

RSS

Computerized decision support tool can assist physicians in prescribing stroke prevention therapy

Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision support tool that uses a combination of patient information and characteristics to assist physicians and patients with decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation.

12 May 2016

Younger women more likely to experience one-year adverse cardiovascular events after PCI

Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. The PROMETHEUS study found that outcomes for both men and women post-PCI are dependent on their baseline risk factors, not their sex.

9 May 2016

Long-term Warfarin use may increase dementia rates in AF patients

A new study of more than 10,000 patients treated long term with the blood thinner, Warfarin, reveals higher rates of dementia for patients with atrial fibrillation versus non-AF patients

5 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Diagnosing heart attacks in 1 hour: an interview with Dr Richard Body

Cardiac troponin is a highly sensitive and specific biomarker for myocardial injury but concentrations in the blood rise over several hours after the onset of an acute myocardial infarction.

28 Apr 2016

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.

26 Apr 2016

Unmet nursing care may contribute to racial/ethnic differences in AMI readmissions

Why are black older adults at higher risk of repeat hospital admission after a heart attack? Treatment at hospitals with higher rates of missed nursing care may be a contributing factor, reports a study in the May issue of Medical Care.

22 Apr 2016

Bosutinib shows 'low' vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia.

21 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Unmet nursing care linked to higher risk of AMI readmissions for older black patients

15 Apr 2016

Inserm study reveals potential of secondary system to improve heart function

Heart failure affects over one million people in France. Although the blood system is the first to have been explored for the purpose of improving heart function, a study by Inserm has revealed the potential of a secondary system that had previously received scant attention.

13 Apr 2016

Entresto drug shows added benefit in symptomatic chronic heart failure

The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.

7 Apr 2016

Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial in nondiabetic patients receiving the Corus CAD blood test.

7 Apr 2016

Respiratory filter mask helps reduce impact of pollution on people with heart failure

The use of a respiratory filter mask, a common practice in China and Japan, among other countries, helps minimize the impact of pollution on people with heart failure during rush-hour traffic in cities such as São Paulo, Brazil.

7 Apr 2016

Losmapimod drug fails to meet primary endpoint in clinical trial

Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent heart attack or urgent coronary revascularization, which includes placement of a stent or coronary artery bypass surgery, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Ischemic postconditioning for STEMI patients shows no clinical outcomes

A large randomized controlled trial of ischemic postconditioning in patients who had experienced the deadliest form of heart attack—ST-segment elevation myocardial infarction (STEMI)—failed to show that this procedure significantly reduces death from any cause or hospitalization for heart failure, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Intravenous beta blockers offer no clinical benefit to patients with STEMI

Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack—ST-segment elevation myocardial infarction (STEMI)—was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Deferred stent implantation fails to show benefit in STEMI patients

Delayed or deferred stent implantation in patients experiencing the deadliest form of heart attack--ST-segment elevation myocardial infarction (STEMI)—failed to reduce death from any cause, hospitalization for heart failure, subsequent heart attacks or the need for a repeat procedure to restore blood flow to the heart, researchers reported at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.

17 Mar 2016

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

15 Mar 2016

Myocardial Infarction News and Research

Computerized decision support tool can assist physicians in prescribing stroke prevention therapy

Younger women more likely to experience one-year adverse cardiovascular events after PCI

Long-term Warfarin use may increase dementia rates in AF patients

Bayer-new phase 3 liver cancer data

Diagnosing heart attacks in 1 hour: an interview with Dr Richard Body

GLP-1 receptor agonist may benefit high-risk diabetes

Unmet nursing care may contribute to racial/ethnic differences in AMI readmissions

Bosutinib shows 'low' vascular, cardiac event risk profile

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Unmet nursing care linked to higher risk of AMI readmissions for older black patients

Inserm study reveals potential of secondary system to improve heart function

Entresto drug shows added benefit in symptomatic chronic heart failure

Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

Respiratory filter mask helps reduce impact of pollution on people with heart failure

Losmapimod drug fails to meet primary endpoint in clinical trial

Ischemic postconditioning for STEMI patients shows no clinical outcomes

Intravenous beta blockers offer no clinical benefit to patients with STEMI

Deferred stent implantation fails to show benefit in STEMI patients

Vascular events in CML may not be linked to TKI therapy

Aralez resubmits NDA package for YOSPRALA to FDA

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News